Xeris Company Profile
✉ Email this page to a colleague
What is the competitive landscape for XERIS, and when can generic versions of XERIS drugs launch?
XERIS has two approved drugs.
There are two US patents protecting XERIS drugs.
There are twenty-three patent family members on XERIS drugs in fifteen countries.
Summary for Xeris
| International Patents: | 23 |
| US Patents: | 2 |
| Tradenames: | 5 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Xeris
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xeris | GVOKE HYPOPEN | glucagon | SOLUTION;SUBCUTANEOUS | 212097-003 | Sep 10, 2019 | RX | Yes | Yes | 9,649,364 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-002 | Sep 10, 2019 | RX | Yes | Yes | 9,649,364 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-002 | Sep 10, 2019 | RX | Yes | Yes | 11,590,205 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Xeris | GVOKE PFS | glucagon | SOLUTION;SUBCUTANEOUS | 212097-001 | Sep 10, 2019 | DISCN | Yes | No | 11,590,205 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Xeris | GVOKE HYPOPEN | glucagon | SOLUTION;SUBCUTANEOUS | 212097-004 | Sep 10, 2019 | RX | Yes | Yes | 11,590,205 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Xeris | GVOKE HYPOPEN | glucagon | SOLUTION;SUBCUTANEOUS | 212097-004 | Sep 10, 2019 | RX | Yes | Yes | 9,649,364 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Xeris Drugs
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
